Physician profile
Amit Alam
NPI 1588906986
$21,133.88
in general payments reported to CMS, 2019-2025
30 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,939 · 2020: $3,421 · 2021: $1,494 · 2022: $2,515 · 2023: $2,063 · 2024: $2,845 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Travel and Lodging: $2,975 · Consulting Fee: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.73 |
| Travel and Lodging | $2,975.47 |
| Consulting Fee | $1,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,375.92 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $4,673.24 | 2023-2025 | Barostim Neo System |
| Abiomed | $3,097.68 | 2019-2023 | Impella |
| Medtronic Vascular, INC. | $2,484.59 | 2019-2020 | |
| Ancora Heart, INC. | $302.75 | 2022 | |
| La Jolla Pharmaceutical Company | $302.53 | 2021-2023 | Giapreza |
| Astrazeneca Pharmaceuticals LP | $292.52 | 2019-2024 | Wainua |
| Novartis Pharmaceuticals Corporation | $243.06 | 2022-2025 | |
| Pfizer INC. | $209.12 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.22 | 2022-2025 | Cobenfy, Camzyos |
| Alnylam Pharmaceuticals INC. | $138.79 | 2024-2025 | Amvuttra |
| Inspire Medical Systems, INC. | $116.41 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.29 | 2024-2025 | Lifevest |
| Edwards Lifesciences Corporation | $76.27 | 2022 | |
| Novo Nordisk INC | $58.44 | 2023-2025 | Wegovy, Ozempic, Saxenda |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.92 | 2021-2025 | Jardiance |
| Livanova USA, INC. | $54.54 | 2020-2023 | Protekduo |
| Scpharmaceuticals INC. | $50.23 | 2025 | |
| Genzyme Corporation | $44.77 | 2024 | |
| Daxor Corporation | $40.00 | 2022 | |
| Bridgebio Pharma, INC. | $38.03 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $36.17 | 2024 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $29.15 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $28.52 | 2025 | Uptravi, Opsumit |
| Nuwellis, INC. | $19.66 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.56 | 2021 | |
| Boston Scientific Corporation | $16.06 | 2023 | Varithena Administration Pack |
| Lantheus Medical Imaging, INC. | $15.78 | 2020 | |
| Heartflow, INC. | $15.06 | 2025 | |
| Medtronic, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.